Article
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis.
The Lancet. Oncology - 1 Sept 2025
Groff Karenna J, Patel Ruchit V, Feng Yang, Ghosh Hia S, Millares Chavez Miguel A, O'Brien Joseph, Chen William C, Nitturi Vijay, Save Akshay V, Youngblood Mark W, Horbinski Craig M, Chandler James P, Ehret Felix, Gui Chloe, Wang Justin Z, Park Kristen, Ajmera Sonia, Rosenblum Marc, Suwala Abigail K, Kresbach Catena, Mount Christopher W, Schüller Ulrich, Santagata Sandro, Sahm Felix, Bale Tejus A, Jackson Christina, Richardson Timothy E, Cai Chunyu, Nassiri Farshad, Zadeh Gelareh, Kaul David, Capper David, Magill Stephen T, Golfinos John G, Sen Chandra, Patel Akash J, Raleigh David R, Moliterno Jennifer, Pacione Donato, Snuderl Matija, Bi Wenya Linda
Abstract excerpt
BACKGROUND: Molecular aberrations have been incorporated into tumour classification guidelines of meningioma. TERT-promoter (TERTp) mutation is associated with worse prognosis and is designated a WHO grade 3 biomarker. However, it remains unclear whether TERTp mutation is context-dependent, with other co-occurring genetic alterations potentially driving its association with prognosis. We sought to characterise...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.